Einloggen

Thematische Bibliographien / Small Cell Lung Cancer / Dissertationen

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Small Cell Lung Cancer.

Dissertationen zum Thema „Small Cell Lung Cancer“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Dissertationen für die Forschung zum Thema "Small Cell Lung Cancer" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Dissertationen für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Sarvi, Sana. "Small cell lung cancer and cancer stem cell-like cells." Thesis, University of Edinburgh, 2014. http://hdl.handle.net/1842/9542.

Der volle Inhalt der Quelle

Annotation:

Small cell lung cancer (SCLC) is a highly aggressive malignancy with extreme mortality and morbidity. Although initially chemo- and radio-sensitive, almost inevitable recurrence and resistance occurs. SCLC patients often present with metastases, making surgery not feasible. Current therapies, rationally designed on underlying pathogenesis, produce in vitro results, however, these have failed to translate into satisfactory clinical outcomes. Recently, research into cancer stem cells (CSCs) has gained momentum and form an attractive target for novel therapies. Based on this concept, CSCs are the

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Kapeleris, Joanna C. "Circulating tumour cells in non-small cell lung cancer." Thesis, Queensland University of Technology, 2022. https://eprints.qut.edu.au/228607/1/Joanna_Kapeleris_Thesis.pdf.

Der volle Inhalt der Quelle

Annotation:

Circulating tumour cells (CTCs) have the potential to transform the management of patients with non-small cell lung cancer (NSCLC). The applications of CTCs can identify clinically actionable targets to predict treatment response and to better understand metastasis. CTCs isolated using microfluidics can be used as prognostic indicators of NSCLC as well as characterizing for markers of immunotherapy (PD-L1), molecular targets (ALK, EGFR). Short term cultures were successfully expanded in 9/70 NSCLC patients and cultured for up to 3 months. Optimization of this novel CTC culture model provides o

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Wang, Wei. "Modulation of immune cell responses by small cell lung cancer cells." Thesis, King's College London (University of London), 2016. https://kclpure.kcl.ac.uk/portal/en/theses/modulation-of-immune-cell-responses-by-small-cell-lung-cancer-cells(7bdc85c2-acd8-4f13-9d2b-e2ce07d1567b).html.

Der volle Inhalt der Quelle

Annotation:

Small Cell Lung Cancer (SCLC) accounts for 15-20% of all lung cancers and kills at least one person every 2 hours in the UK. There is no effective treatment and overall 2-year survival is less than 5%. Patients with SCLC have poorly understood local and systemic immune defects. Previous studies have shown several important defects in cell-mediated immune responses in patients with SCLC. A better understanding of interactions between SCLC tumour cells and immune cells may lead to the development of novel therapeutic approaches. There is increasing recognition that immunological biomarkers may a

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Oosterhout, Anselmus Gerardus Maria van. "Small cell lung cancer and brain metastasis." Maastricht : Maastricht : Rijksuniversiteit Limburg ; University Library, Maastricht University [Host], 1995. http://arno.unimaas.nl/show.cgi?fid=6643.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Seute, Tatjana. "Neurologic complications in small cell lung cancer." Maastricht : Maastricht : Universiteit Maastricht ; University Library, Universiteit Maastricht [host], 2008. http://arno.unimaas.nl/show.cgi?fid=9520.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Macaulay, Valentine. "Growth regulation in small cell lung cancer." Thesis, Imperial College London, 1989. http://hdl.handle.net/10044/1/47547.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Sikkink, Stephen K. "Genetic pathology of non-small cell lung cancer." Thesis, University of Liverpool, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.250405.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Brena, Romulo Martin. "Aberrant DNA methylation in human non-small cell lung cancer." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1172083621.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Wong, Wing-sze, and 黃詠詩. "Fusion genes in non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43781378.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Ng, Sheng Rong. "CRISPR-mediated interrogation of small cell lung cancer." Thesis, Massachusetts Institute of Technology, 2018. http://hdl.handle.net/1721.1/117782.

Der volle Inhalt der Quelle

Annotation:

Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biology, 2018.<br>This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.<br>Cataloged student-submitted from PDF version of thesis. Vita.<br>Includes bibliographical references.<br>Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine lung carcinoma that remains among the most lethal of solid tumor malignancies. Despite decades of research, treatment outcomes for SCLC remain very poor, highlighting the need for novel appr

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Lawson, Malcolm Hedley. "Determinants of chemoresistance in small cell lung cancer." Thesis, University of Cambridge, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.609102.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Hodkinson, Philip Simon. "Tumour microenvironment interactions of small cell lung cancer." Thesis, University of Edinburgh, 2009. http://hdl.handle.net/1842/4254.

Der volle Inhalt der Quelle

Annotation:

Small cell lung cancer (SCLC) is characterised by rapid growth, early metastatic spread and poor long-term survival. The tumour is initially sensitive to chemotherapy and thus objective response rates are high. Unfortunately, this response is often short-lived and SCLC recurs with acquired drug resistance, resulting in early patient death. Despite intensive chemo- and radiotherapy regimes survival has not improved significantly in 20 years. Prior research suggests a critical role for the tumour microenvironment in the pathogenesis of other cancers. Therefore, investigating interactions between

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Swinson, Daniel. "Hypoxic markers in non-small cell lung cancer." Thesis, University of Leicester, 2004. http://hdl.handle.net/2381/29476.

Der volle Inhalt der Quelle

Annotation:

Hypoxia is an important factor in the pathogenesis of solid tumours. Hypoxia inducible factors (HIF)-1alpha and HIF-2alpha are transcription factors that in part mediate the cellular response to hypoxia. These transcription factors are involved in the regulation of angiogenesis, anaerobic metabolism, pH homeostasis, erythropoiesis and cell death.;Immunohistochemical (IHC) assays were optimised for HIF-1alpha and one of its transcriptional targets, Carbonic Anhydrase (CA) IX. Attempts to optimise an IHC assay for HIF-2alpha failed to produce reproducible staining. A scoring system was also devi

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Moka, Nagaishwarya, Manisha Nukavarapu, Jennifer Phemister, and Mckinney Jason. "Small cell lung cancer(SCLC) disguised as Dysphagia." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/asrf/2019/schedule/168.

Der volle Inhalt der Quelle

Annotation:

Common presenting symptoms of Lung cancer are cough, hemoptysis, chest pain, dyspnea, pleurisy. Dysphagia is a very uncommon presenting feature of Lung cancer. Incidence of Dysphagia in Lung cancer is unclear from Literature. Causes of Dysphagia in case of Lung cancer are Anatomically classified as Oropharyngeal and Esophageal. Causes of oropharyngeal dysphagia are oral candidiasis, oropharyngeal Metastasis of Lung cancer. Causes of esophageal dysphagia are Cervical or Mediastinal Lymphadenopathy, Motor dysfunction because of Brain stem Metastasis, Lambert eaton syndrome, Esophageal candidiasi

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Wong, Wing-sze. "Fusion genes in non-small cell lung cancer." Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B43781378.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Wong, Kit-man Sunny, and 王傑民. "Isolation and characterization of cancer stem cells in non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B47250665.

Der volle Inhalt der Quelle

Annotation:

Tumor heterogeneity has long been observed and recognized as a challenge to cancer therapy. The cancer stem cell (CSC) model is one of the hypotheses proposed to explain such a phenomenon. A specific cancer stem cell marker has not been determined for non-small cell lung cancers (NSCLC), preventing the definitive evaluation of whether the biology of NSCLC is governed by the CSC model. This study aimed to analyze the expression of candidate CSC markers and using the identified putative marker, to isolate CSC and determine the applicability of the CSC model in NSCLC. The expression or

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Brattström, Daniel. "Angiogenesis related markers in non-small cell lung cancer /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl.[distributör], 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3558.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

陳潔盈 and Kit-ying Loucia Chan. "Expression analysis of Candidate cancer genes in non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B45011163.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Stordal, Britta Kristina. "Regrowth resistance in platinum-drug resistant small cell lung cancer cells." Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and The University of Sydney, 2007. http://hdl.handle.net/2123/2467.

Der volle Inhalt der Quelle

Annotation:

Doctor of Philosophy (PhD)<br>The H69CIS200 cisplatin-resistant and H69OX400 oxaliplatin-resistant cell lines developed as part of this study, are novel models of low-level platinum resistance. These resistant cell lines do not have common mechanisms of platinum resistance such as increased expression of glutathione or decreased platinum accumulation. Rather, these cell lines have alterations in their cell cycle allowing them to proliferate rapidly post drug treatment in a process known as ‘regrowth resistance’. This alteration in cell cycle control has come at the expense of DNA repair capaci

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Stordal, Britta. "Regrowth resistance in platinum-drug resistant small cell lung cancer cells." Connect to full text, 2006. http://hdl.handle.net/2123/2467.

Der volle Inhalt der Quelle

Annotation:

Thesis (Ph. D.)--University of Sydney, 2007.<br>Title from title screen (viewed 10 June 2008). Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the Discipline of Medicine, Faculty of Medicine. Degree awarded 2007; thesis submitted 2006. Includes bibliographical references. Also available in print form.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Brattström, Daniel. "Angiogenesis Related Markers In Non-Small Cell Lung Cancer." Doctoral thesis, Uppsala University, Oncology, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3558.

Der volle Inhalt der Quelle

Annotation:

<p>This thesis investigated the predictive and the prognostic powers of angiogenesis related markers in both operable and inoperable non-small cell lung cancer (NSCLC) patients.</p><p>In the first and second study, we investigated the serological fractions of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in 2 cohorts of patients with either operable or inoperable NSCLC. </p><p>Regarding operable NSCLC, we demonstrated significant correlations between VEGF and tumour volume and overall survival. Regarding bFGF, significant correlations with recurrent diseas

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Lam, Chi-leung David. "Gene expression profiling in non-small cell lung cancer." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/hkuto/record/B38585777.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Ho, Chung-man. "Non-small cell lung cancer from bench to bedside /." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/hkuto/record/B39432592.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Berrieman, Helen Katherine. "Resistance to chemotherapy in non-small cell lung cancer." Thesis, University of Hull, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415803.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Furon, Emeline. "Phenotypic variations and chemosensitivity in small cell lung cancer." Thesis, Cardiff University, 2008. http://orca.cf.ac.uk/54491/.

Der volle Inhalt der Quelle

Annotation:

Many complex properties of cancer cells are effectively under selection within the in vivo microenvironment or following therapeutic insult. This critical combination of instability and shifting selection drives the heterogeneity of tumour cell populations in terms of many critical features. Small cell lung cancer (SCLC) is an aggressive, rapidly metastasizing neoplasm with an ability to develop resistance against chemotherapeutic agents. New SCLC therapeutic strategies are urgently needed that contain spreading disease without further compromising tumour chemosensitivity. Variants for attachm

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Ohri, Chandra. "The immune response to non-small cell lung cancer." Thesis, University of Leicester, 2010. http://hdl.handle.net/2381/8195.

Der volle Inhalt der Quelle

Annotation:

Non-small cell lung cancer (NSCLC) is responsible for more deaths worldwide than any other cancer. Currently, 5-year survival for patients with stage IA disease is just 67%. Chemotherapy offers no cure at present for patients with NSCLC. It is now recognised that the immune system plays a significant role in both tumour modulation and progression. Therefore, a better understanding of immune responses to NSCLC may lead to the development of novel therapies. In these studies, I have investigated, using immunohistochemistry, the microlocalisation of macrophage and mast cell phenotypes (as well as

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Ho, Chung-man, and 何重文. "Non-small cell lung cancer: from bench to bedside." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B39432592.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Lam, Chi-leung David, and 林志良. "Gene expression profiling in non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B38585777.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Bryant, Jennifer. "Neuroendocrine and epithelial markers of small cell lung cancer." Thesis, University of Manchester, 2015. https://www.research.manchester.ac.uk/portal/en/theses/neuroendocrine-and-epithelial-markers-of-small-cell-lung-cancer(c7c51e2c-6443-4021-b2ff-469966cd10b6).html.

Der volle Inhalt der Quelle

Annotation:

Small cell lung cancer (SCLC) is an extremely aggressive disease characterized by early metastasis and acquired resistance to therapy. SCLC is distinguished by its neuroendocrine (NE) component; the role of which is not fully understood in metastasis and response to therapy. Patients respond exceptionally well to first round chemotherapy; however, relapse with therapy-resistant tumours is virtually inevitable. Hypoxic regions within tumours can contribute towards metastasis and therapy resistance, highlighting hypoxia-targeted therapy as a novel approach for improving treatment for SCLC patien

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Agrawal, Vishesh. "Quantitative Imaging Analysis of Non-Small Cell Lung Cancer." Thesis, Harvard University, 2016. http://nrs.harvard.edu/urn-3:HUL.InstRepos:27007763.

Der volle Inhalt der Quelle

Annotation:

Quantitative imaging is a rapidly growing area of interest within the field of bioinformatics and biomarker discovery. Due to the routine nature of medical imaging, there is an abundance of high-quality imaging linked to clinical and genetic data. This data is particularly relevant for cancer patients who receive routine CT imaging for staging and treatment purposes. However, current analysis of tumor imaging is generally limited to two-dimensional diameter measurements and assessment of anatomic disease spread. This conventional tumor-node-metastasis (TNM) staging system stratifies patients t

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Holgersson, Georg. "Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC)." Doctoral thesis, Uppsala universitet, Experimentell och klinisk onkologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-327925.

Der volle Inhalt der Quelle

Annotation:

Background: Non-small cell lung cancer (NSCLC) is the cancer disease with the highest mortality globally. About 75% of NSCLC patients are diagnosed in an advanced stage where surgical treatment is not possible. For patients with locally advanced disease without distant metastases, the treatment of choice is curatively intended radiotherapy. However, this treatment has considerable side effects and many patients relapse. To individualize the treatment strategy for these patients, it is essential to have as much prognostic information as possible. The aim of this thesis was to investigate the pr

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

PASSIGLIA, Francesco. "Immune-Biomarkers in Advanced Non-Small Cell Lung Cancer." Doctoral thesis, Università degli Studi di Palermo, 2021. http://hdl.handle.net/10447/514194.

Der volle Inhalt der Quelle

Annotation:

N.A<br>Background: Developing personalized immunotherapy-based approaches, through the identification of predictive immune-related biomarkers, is still a main topic for translational lung cancer research. In the present study we investigated whether baseline tissue “immune-related gene signatures”, as well as plasma chemo-cytokines profiles, could predict sensitivity/resistance to immune-checkpoint inhibitors in pre-treated patients with advanced non-small cell lung cancer (NSCLC). Methods: From September 2015 to September 2018, 150 patients with previously treated advanced NSCLC who rec

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Xinarianos, George. "Genetic alterations in non-small cell lung carcinomas." Thesis, University of Liverpool, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.343688.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Chan, Kit-ying Loucia. "Expression analysis of Candidate cancer genes in non-small cell lung cancer /." View the Table of Contents & Abstract, 2007. http://sunzi.lib.hku.hk/hkuto/record/B38480360.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Baker, Amanda F., Neale T. Hanke, Barbara J. Sands, Liliana Carbajal, Janet L. Anderl, and Linda L. Garland. "Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models." BioMed Central, 2014. http://hdl.handle.net/10150/610318.

Der volle Inhalt der Quelle

Annotation:

BACKGROUND: Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1B studies of CFZ reported signals of clinical activity in solid tumors, including small cell lung cancer (SCLC). The aim of this study was to investigate the activity of CFZ in lung cancer models. METHODS: A diverse panel of human lung cancer cell lines and a SHP77 small cell lung cancer xenograft model were used to investigate the anti-tumor activity of CFZ. RESULTS: CFZ treatment inhibit

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

譚郭雅欣 and Gloria Tam. "Non-small cell lung cancer clinical trials on new medicines." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B41711956.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Daly, Maria Catherine. "Chromosome 3 deletion mapping in human small cell lung cancer." Thesis, University of Cambridge, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.304095.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Acheampong, Emmanuel. "Assessment of circulating tumour cells in lung cancer patients." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2022. https://ro.ecu.edu.au/theses/2554.

Der volle Inhalt der Quelle

Annotation:

Lung cancer is among the most prevalent forms of cancer and remains the leading cause of cancer-associated deaths globally. Traditionally, lung cancers are classified as either non-small cell lung cancer (NSCLC) (85%) or small cell lung cancer (SCLC) (15%). About 60% of all cases are diagnosed at an advanced stage, at which the 5-year survival is only 4%. Anti-programmed cell death-1 and its ligand 1 (anti-PD-1/PD-L1) therapies have significantly improved the outcomes for lung cancer patients in recent years. However, prognosis and understanding of an individual patient’s lung cancer are often

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Tai, Lai-shan. "Molecular genetic characterizations of human non-small cell lung cancer." Click to view the E-thesis via HKUTO, 2005. http://sunzi.lib.hku.hk/hkuto/record/B31375315.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Casadevall, Aguilar David. "Heterogeneity of biomarker expression in non-small cell lung cancer." Doctoral thesis, Universitat Autònoma de Barcelona, 2017. http://hdl.handle.net/10803/457975.

Der volle Inhalt der Quelle

Annotation:

L’èxit de de la medicina de precisió en oncologia depèn, en gran mesura, d’una adequada selecció dels pacients que rebran teràpies dirigides contra dianes específiques del seu tumor. Per poder seleccionar els pacients, és indispensable disposar de biomarcadors amb valor predictiu que informin les decisions terapèutiques. MET i PD-L1 són dos receptors de membrana rellevants en la biologia del carcinoma pulmonar no microcític (CPNM). MET és un oncogen i l’activació de la seva via es troba relacionada amb múltiples processos pro-tumorals com són la proliferació i la motilitat cel·lulars, així c

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Tong, Wing-yee. "Studies on non-small cell lung cancer with EGFR mutation /." View the Table of Contents & Abstract, 2005. http://sunzi.lib.hku.hk/hkuto/record/B31495333.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Cox, Giles. "Angiogenesis and matrix metalloproteinases in non-small cell lung cancer." Thesis, University of Leicester, 2000. http://hdl.handle.net/2381/29608.

Der volle Inhalt der Quelle

Annotation:

The aim of this study was to evaluate potential invasive and metastatic pathways in order to develop a biological prognostic model for operable NSCLC. Initially an immunohistochemical study of angiogenesis, growth factor receptors (EGFR, c-erbB-2), regulators of apoptosis (p53, Bcl-2) and matrix metalloproteinases and their inhibitors (MMP-2, MMP-9 and TIMP-2) was performed in a retrospective series of resected NSCLC tumours. Chalkley counting of CD34-immunostained microvessels was used as an indirect measure of angiogenesis. A high Chalkley count was an independent marker of poor outcome. Bcl

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Tai, Lai-shan, and 戴麗珊. "Molecular genetic characterizations of human non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B31375315.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Tong, Wing-yee, and 唐穎儀. "Studies on non-small cell lung cancer with EGFR mutation." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B45010432.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Koch, Andrea. "Clinical Aspects of Inflammation in Non-small Cell Lung Cancer." Doctoral thesis, Linköpings universitet, Internmedicin, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-68749.

Der volle Inhalt der Quelle

Annotation:

Lung cancer is the most common cause of cancer death worldwide, with about 1.2 million deaths every year. In Sweden, about 3500 new cases are diagnosed every year. The majority of patients presents with advanced non-small cell lung cancer (NSCLC) and is treated with palliative intent. Standard treatment in these patients in performance status 0-2 is combination chemotherapy. Radiotherapy may be added for palliative purposes. Median survival time with such treatment is 6-10 months. New treatment strategies are urgently needed. There is growing evidence for a link between cancer and inflammation

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Brauneis, Alison Dooley. "Investigating the initiation and progression of small cell lung cancer." Thesis, Massachusetts Institute of Technology, 2011. http://hdl.handle.net/1721.1/63063.

Der volle Inhalt der Quelle

Annotation:

Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Biology, 2011.<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references.<br>Small cell lung cancer (SCLC) comprises 18% of all lung cancer cases and is an aggressive disease with a five-year survival rate of less than 5%, mainly due to the advanced nature of the disease at the time of diagnosis. Despite the need to better understand this disease, the genetic lesions that contribute to SCLC remain poorly characterized. To investigate the genetic aberrations that occur in SCLC, we analyzed the copy number alt

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Kouverianou, Eleni. "Galectin-3 regulation of non small cell lung cancer growth." Thesis, University of Edinburgh, 2014. http://hdl.handle.net/1842/17891.

Der volle Inhalt der Quelle

Annotation:

Galectin-3 is a β-galactoside binding lectin expressed in tumour cells and macrophages and has been associated with increased malignancy in a variety of cancers. Previous work has shown that galectin-3 is an important regulator of macrophage function, promoting an alternative (M2) phenotype which potentiates chronic inflammation and fibrosis. Tumour associated macrophages (TAMs) adopt an M2 phenotype and are thought to promote tumour growth by down regulating T cell effector function and promoting angiogenesis. This project examines the hypothesis that host galectin-3 promotes lung cancer grow

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Usó, Marco Marta. "ANALYSIS OF IMMUNOREGULATORY BIOMARKERS IN NON-SMALL CELL LUNG CANCER." Doctoral thesis, Universitat Politècnica de València, 2015. http://hdl.handle.net/10251/51283.

Der volle Inhalt der Quelle

Annotation:

[EN] Lung cancer is the leading cause of cancer-related death worldwide, and is the third most common cancer type; it can be classified into two subgroups based on histology: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The 5-year survival still remains poor and despite the existence of several distinct tumour phenotypes, therapeutic decisions are mainly based on clinical features such as stage or performance status. This highlights the need for new diagnostic and prognostic biomarkers in different types of samples (such as blood, fresh-frozen tissue or formalin-fixed,

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Deskin, Brian J. "Histone deacetylase 6 functions in non-small cell lung cancer." Thesis, Tulane University, 2017. http://pqdtopen.proquest.com/#viewpdf?dispub=10195328.

Der volle Inhalt der Quelle

Annotation:

<p> Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide in both men and women. Of relevance to our research presented herein are the Transforming growth factor β (TGF-β) signaling pathways and the heat shock response in the context of NSCLC. Dysregulation of TGF-β signaling often results in disease and is a common feature of many cancers including NSCLC where it governs cell fate and epithelial plasticity through the epithelial-to-mesenchymal transition (EMT). Another key feature of oncogenic TGF-β signaling is the crosstalk with other

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Tam, Gloria. "Non-small cell lung cancer clinical trials on new medicines." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B41711956.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!